Leerink Partnrs Analysts Boost Earnings Estimates for TWST

Twist Bioscience Co. (NASDAQ:TWST) – Stock analysts at Leerink Partnrs boosted their Q2 2025 earnings per share estimates for Twist Bioscience in a research report issued to clients and investors on Monday, February 3rd. Leerink Partnrs analyst P. Souda now anticipates that the company will earn ($0.59) per share for the quarter, up from their previous estimate of ($0.62). The consensus estimate for Twist Bioscience’s current full-year earnings is ($2.27) per share. Leerink Partnrs also issued estimates for Twist Bioscience’s Q4 2025 earnings at ($0.50) EPS, FY2025 earnings at ($2.18) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.38) EPS and FY2026 earnings at ($1.77) EPS.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. Twist Bioscience’s quarterly revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.75) earnings per share.

Several other brokerages have also weighed in on TWST. JPMorgan Chase & Co. lifted their price objective on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a report on Tuesday. Scotiabank lifted their target price on shares of Twist Bioscience from $54.00 to $62.00 and gave the stock a “sector outperform” rating in a research note on Tuesday. Robert W. Baird upped their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday. TD Cowen reiterated a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. Finally, Leerink Partners increased their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $53.80.

Twist Bioscience Stock Up 3.2 %

Twist Bioscience stock opened at $53.66 on Thursday. The company has a market capitalization of $3.19 billion, a P/E ratio of -14.91 and a beta of 1.87. The firm has a 50 day moving average price of $48.74 and a 200-day moving average price of $46.27. Twist Bioscience has a twelve month low of $27.41 and a twelve month high of $60.90.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of the business. The Manufacturers Life Insurance Company raised its stake in Twist Bioscience by 3.7% during the second quarter. The Manufacturers Life Insurance Company now owns 31,064 shares of the company’s stock valued at $1,531,000 after purchasing an additional 1,104 shares in the last quarter. SG Americas Securities LLC grew its stake in Twist Bioscience by 407.1% in the third quarter. SG Americas Securities LLC now owns 10,958 shares of the company’s stock worth $495,000 after purchasing an additional 8,797 shares in the last quarter. CWM LLC boosted its position in Twist Bioscience by 141.9% during the 3rd quarter. CWM LLC now owns 5,894 shares of the company’s stock valued at $266,000 after acquiring an additional 3,457 shares in the last quarter. Exchange Traded Concepts LLC grew its position in shares of Twist Bioscience by 30.1% in the 3rd quarter. Exchange Traded Concepts LLC now owns 20,141 shares of the company’s stock worth $910,000 after buying an additional 4,661 shares during the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its holdings in shares of Twist Bioscience by 30.7% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 10,658 shares of the company’s stock valued at $482,000 after purchasing an additional 2,505 shares during the last quarter.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 5,886 shares of the business’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the sale, the chief financial officer now directly owns 110,096 shares in the company, valued at $4,762,752.96. The trade was a 5.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Emily M. Leproust sold 5,200 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $256,620.00. Following the completion of the sale, the chief executive officer now owns 667,318 shares of the company’s stock, valued at $32,932,143.30. This trade represents a 0.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 59,002 shares of company stock valued at $2,851,681 in the last quarter. 3.01% of the stock is owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.